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Objectives: Tenofovir (TDF) is increasingly used in second-line
antiretroviral treatment (ART) in sub-Saharan Africa. We compared
outcomes of second-line ART containing and not containing TDF in
cohort studies from Zambia and the Republic of South Africa (RSA).
Methods: Patients aged 16 years and older starting protease-
inhibitor–based second-line ART in Zambia (1 cohort) and RSA
(5 cohorts) were included. We compared mortality, immunological
failure (all cohorts), and virological failure (RSA only) between
patients receiving and not receiving TDF. Competing risk models
and Cox models adjusted for age, sex, CD4 count, time on ﬁrst-line
ART, and calendar year were used to analyze mortality and treatment
failure, respectively. Hazard ratios (HRs) were combined in ﬁxed-
effects meta-analysis.
Findings: 1687 patients from Zambia and 1556 patients from RSA,
including 1350 (80.0%) and 206 (13.2%) patients starting TDF, were
followed over 4471 person-years. Patients on TDF were more likely to
have started second-line ART in recent years and had slightly higher
baseline CD4 counts than patients not on TDF. Overall, 127 patients
died, 532 were lost to follow-up, and 240 patients developed immuno-
logical failure. In RSA, 94 patients had virologic failure. Combined HRs
comparing TDF with other regimens were 0.60 (95% conﬁdence interval
[CI]: 0.41 to 0.87) for immunologic failure and 0.63 (0.38–1.05) for
mortality. The HR for virologic failure in RSA was 0.28 (0.09–0.90).
Conclusions: In this observational study, patients on TDF-
containing second-line ART were less likely to develop treatment
failure than patients on other regimens. TDF seems to be an effective
component of second-line ART in southern Africa.
Key Words: tenofovir, second-line antiretroviral therapy, southern
Africa, treatment failure, mortality
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INTRODUCTION
Despite the unprecedented scale-up of antiretroviral
treatment (ART) in resource-constrained settings, the pro-
portion of patients switching to second-line ART after failing
a ﬁrst-line regimen is low in many resource-limited coun-
tries.
1 Earlier detection of treatment failure and switching
to second-line protease-inhibitor (PI)–based ART probably
reduces mortality,
2 but second-line regimens remain consider-
ably more expensive than ﬁrst-line regimens. Only few studies
have described clinical outcomes of patients on second-line
therapy in sub-Saharan Africa.
3–6
As genotypic drug-resistance testing is not routinely
available in the region, the World Health Organization
(WHO) recommends the use of standardized second-line ART
consisting of a ritonavir-boosted PI plus 2 nucleoside reverse
transcriptase inhibitors (NRTIs).
7 The NRTI backbone should
include at least one new agent. Tenofovir (TDF) is increasingly
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viously exposed to this drug. In southern Africa, TDF has only
recently been introduced for use in ﬁrst-line ART and most
patients failing their ﬁrst-line regimen are therefore eligible to
receive this drug in second-line ART. Although studies from
Europe and North America showed favorable clinical out-
comes in patients treated with TDF-containing salvage ART,
8,9
outcomes of second-line regimens containing and not containing
TDF have not been compared so far in southern Africa.
HIV-1 subtype C variant represents approximately 50%
of global HIV infections and is most prevalent in southern
Africa. The K65R mutation, which is associated with TDF
resistance, is more frequent in HIV-1 subtype C compared with
subtype B viruses, especially when suboptimal ﬁrst-line
regimens, including stavudine (D4T) or didanosine (ddI), are
used.
10–12 A study from Malawi showed that 23% of patients
failing ﬁrst-line ART developed the K65R mutation even with-
out prior exposure to TDF.
11 In South Africa, where routine
viral load monitoring shortens the time patients spend on failing
ﬁrst-line regimens, the proportion of patients with this mutation
was much lower.
13–15 In Malawi, clinical outcomes after 1 year
were not affected by resistance.
6 We compared outcomes in
patients receiving TDF-containing second-line ART with those
on other second-line regimens in a collaborative analysis of
6 cohorts in Zambia and the Republic South Africa (RSA).
METHODS
ART Programmes
The International epidemiological Databases to Evaluate
AIDS in Southern Africa (IeDEA-SA) network is a regional
collaboration of ART programmes.
16 Data are collected at
ART initiation (baseline) and each follow-up visit, using stan-
dardized instruments, and transferred to data centres at the
Universities of Cape Town, RSA and Bern, Switzerland. All
sites have ethical approval to collect data and to participate
in IeDEA-SA.
We included all cohorts with more than 50 patients on
second-line ART and 10 or more patients on TDF and not on
TDF. Six cohorts met inclusion criteria: the Centre for Infectious
Disease Research in Zambia (MoH-CIDRZ) programme in
Lusaka, Zambia and 5 cohorts from RSA: Aurum Institute
(community and workplace ART program) and Themba Lethu
clinic in Johannesburg, and the Khayelitsha and Tygerberg ART
programs in Cape Town. In RSA, viral load and CD4 cell counts
are monitored every 6 months during the ﬁrst year of ART and
then yearly. In Zambia, CD4 counts are monitored every 6
months but viral load measurements are not routinely performed.
All treatment programmes trace patients lost to follow-up.
Eligibility Criteria
All patients aged 16 years and older who started
a second-line ART regimen were included. We deﬁned
second-line regimens according to the most recent WHO
treatment guidelines as a boosted PI-based regimen, which
followed a ﬁrst-line regimen of 1 NNRTI and 2 NRTIs. At least
one component of the NRTI backbone had to be replaced by a
drug characterized by different resistance mutations pathways.
For example, a change from lamivudine (3TC)/D4T to 3TC/
zidovudine (AZT) was not considered an eligible backbone
change. Patients with ineligible backbone changes and patients
treated with a TDF-containing ﬁrst-line regimen were excluded.
The selection of study participants in Zambia and the RSA are
shown in the Supplemental Digital Content (see Figures S1
and S2, http://links.lww.com/QAI/A340).
Outcomes
We examined time to immunological failure, time to
virological failure, and time to death, deﬁning treatment
failure as proposed by WHO. Brieﬂy, there are 3 possible
criteria for immunological failure: (1) a fall of CD4 count to
baseline or below, (2) a 50% fall from ontreatment peak
value, and (3) persistent CD4 count levels below 100 cells per
microliters. Patients were considered to experience immuno-
logical failure if at least one of the 3 criteria were fulﬁlled
on 2 consecutive CD4 cell measurements within 1 year.
Virological failure, deﬁned as 2 consecutive viral load
measurements above 5000 copies per milliliter within a year,
was assessed in the South African cohorts.
Statistical Analyses
Characteristics at the start of second-line ART were
compared between patients on second-line regimens contain-
ing and not containing TDF using x2 and Mann–Whitney
tests. We compared rates of immunological failure and viro-
logical failure in Cox regression models, measuring time from
6 months after switching to second-line ART. We used com-
peting risk cumulative incidence curves
17 and competing risk
regression models according to Fine and Gray
18 to compare
mortality, measuring time from switching to second-line ART.
Standard Kaplan–Meier curves ignore the competing risks of
death and loss to follow-up (LTFU) and may produce biased
results.
19 All regression models included the variables gender,
age (16–29, 30–39, or 40 years and over), CD4 cell count
(0–49, 50–99, 100–199, more than 200 cells per microliters
or “not measured”) at the start of second-line ART, time on
ﬁrst-line before switching to second-line ART (less than 18,
18–36, or more than 36 months) and calendar year of starting
second-line ART (before 2007, 2007, 2008, 2009, and 2010).
All analyses were done separately for Zambia and RSA.
Subdistribution hazard ratios (sHRs) and HRs were then
combined in (inverse variance weighted) ﬁxed-effects meta-
analysis and shown in a stratiﬁed forest plot. Finally, to assess
the effect of the ﬁrst-line backbone on second-line outcomes, we
examined whether the use of D4T in the ﬁrst-line ART regimen
predicted immunological failure in patients on TDF-containing
second-line regimen. All statistical analyses were performed
using Stata software version 11 (College Station, TX).
RESULTS
ART Programmes and Patients Characteristics
Table 1 shows the composition of cohorts. A total of
3243 patients on second-line ART, including 1556 (48.0%)
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Most patients were women in all cohorts except the work-
place cohort in South Africa, which was dominated by
male miners. The median age ranged from 32 years in Khaye-
litsha to 45 years in the Aurum workplace cohort. In Zambia,
80% of patients were on TDF-based second-line ART,
whereas in RSA this percentage ranged from 4% to 25%.
Crude mortality rates were similar across South African
cohorts except for the Aurum community cohort for which
mortality was considerably lower, probably because of under
ascertainment of deaths. Such under ascertainment may also
explain the lower mortality in Zambia compared with RSA.
Both in Zambia and RSA, the proportion of patients on
a TDF containing second-line regimen increased over the
years, with the exception of a slight decrease in Zambia in
2010 (Table 2). The median age at start of second-line ART
TABLE 1. Characteristics of Participating Antiretroviral Therapy (ART) Programmes
Sites
No.
Patients
Female
(%)
Median
Age in
Years
(IQR)
No. Second-
Line ART
With TDF
(%)
Viral Load
Monitoring
Follow-Up
Time on
Second-Line
ART (py)
Mortality
(95% CI)
(Per 1000 py)
LTFU (95% CI)
(Per 1000 py)
South Africa
Aurum-C 323 209 (65) 38 (32–44) 80 (25) Yes 309 6.5 (1.6 to 25.9) 145.7 (108.8 to 195.1)
Aurum-W 262 15 (6) 45 (38–51) 10 (4) Yes 331 45.2 (27.3 to 75.0) 165.8 (127.3 to 216.0)
Khayelitsha 197 144 (73) 32 (28–40) 13 (7) Yes 227 30.8 (14.7 to 64.7) 61.7 (36.5 to 104.1)
Themba
Lethu
562 341 (61) 36 (32–43) 81 (14) Yes 766 35.3 (24.2 to 51.4) 105.8 (85.1 to 131.5)
Tygerberg 212 139 (66) 35 (31–42) 22 (10) Yes 329 39.5 (22.9 to 68.0) 54.6 (34.4 to 86.7)
Zambia
CIDRZ 1687 954 (57) 38 (33–45) 1350 (80) No 2508 25.1 (19.6 to 32.2) 127.2 (114.0 to 141.9)
Total 3243 1802 (55.6) 38 (32–45) 1556 (48.0) 4471 28.4 (23.9 to 33.8) 119.0 (109.3 to 129.5)
Aurum-C, Aurum Community cohort; Aurum-W, Aurum workplace cohort; py, person-years.
TABLE 2. Patient Characteristics at Start of Second-Line Antiretroviral Therapy
Zambia South Africa
All Patients
(N = 3243)
TDF
(N = 1350)
No TDF
(N = 337) P
TDF
(N = 206)
No TDF
(N = 1350) P
Female
gender (%)
1802 (55.6) 757 (56.1) 197 (58.5) 0.43 137 (66.5) 711 (52.7) ,0.001
Median age at
start (IQR)
38 (32–45) 39 (33–45) 37 (32–43) 0.003 37 (32–43) 38 (32–45) 0.37
Median CD4
count at
start (IQR)
172 (95–267) 161 (92–261) 135 (77–242) 0.05 206 (97–339) 185 (103–270) 0.05
Missing (%) 349 (10.8) 183 (13.6) 46 (13.6) 23 (11.1) 97 (7.2)
Median time on
ﬁrst-line ART
in months
(IQR)
27 (17–38) 33 (23–43) 27 (18–35) ,0.001 24 (15–34) 22 (14–32) 0.04
Calendar year (%) ,0.001 ,0.001
Before 2007 405 (12.5) 5 (0.4) 53 (15.7) 22 (10.7) 325 (24.1)
2007 695 (21.4) 164 (12.2) 122 (36.2) 32 (15.5) 377 (27.9)
2008 909 (28.0) 445 (33.0) 57 (16.9) 44 (21.4) 363 (26.9)
2009 889 (27.4) 487 (36.1) 59 (17.5) 86 (41.8) 257 (19.0)
2010 345 (10.6) 249 (18.4) 46 (13.7) 22 (10.7) 28 (2.1)
Most common
second-line
ART backbone
(%)
FTC/TDF
(37.5)
FTC/TDF
(85.8)
DDI/ABC
(79.8)
TDF/FTC
(28.4)
DDI/AZT
(71.1)
DDI/AZT
(29.8)
3TC/TDF
(8.0)
ABC/3TC
(16.6)
3TC/TDF
(26.9)
DDI/ABC
(17.5)
DDI/ABC
(15.6)
FTC/AZT/
TDF (5.9)
DDI/3TC (1.2) AZT/3TC/TDF
(12.2)
DDI/D4T
(2.4)
Categorical variables are compared with x2, continuous variables with Mann–Whitney tests. Viral load is routinely monitored in South Africa only.
3TC, lamivudine; ABC, abacavir; AZT, zidovudine; DDI, didanosine; FTC, emtricitabine; IQR, interquartile range.
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both treatment groups in RSA. Conversely, the sex distribu-
tion was similar in Zambia, whereas in RSA, women were
more likely to start a TDF containing regimen than men.
In both countries, patients receiving TDF-containing regi-
mens had higher CD4 cell counts and had spent more time
on their ﬁrst-line regimen before switching to second-line
ART than those on other regimens. Most patients (3225
patients; 99.4%) were treated with second-line regimens con-
taining ritonavir-boosted lopinavir (LPV/r) and 1468 (87.0%)
of the patients not on a TDF-containing second-line regimen
had a backbone of DDI/AZT or DDI/ABC.
Descriptive Analyses of Treatment Failure,
Mortality, and LTFU
Analyses of immunological treatment failure were
based on 2330 patients (71.8% of total study population)
with at least 6 months of follow-up after starting second-line
ART. Virological failure was examined in 992 patients
(63.8% of patients treated in RSA). Over 2782 person-years,
94 patients (7.9%) on TDF, and 146 patients (12.8%) on other
second-line regimens developed immunological failure. The
crude incidence rate of immunological failure was 69.9 (95%
CI: 57.1 to 85.6) per 1000 person-years in the TDF group and
101.6 (86.4–119.4) per 1000 person-years in the other group.
In South Africa, 3 patients (2.7%) in the TDF group and 107
patients (12.1%) in the group without TDF experienced viro-
logical failure. Figure 1 shows the Kaplan–Meier curves of
immunological failure in Zambia and virological failure in
South Africa, by treatment group.
Over 4471 person-years, 127 patients (3.9%) died and
532 (16.4%) were LTFU (Table 1). Crude rates per 1000
person-years ranged from 6.5 (95% CI: 1.6 to 25.9) to 45.2
(27.3 to 75.0) for mortality and from 54.6 (34.4 to 86.7) to
165.8 (127.3 to 216.0) for LTFU. Figure 2 shows the cumu-
lative incidence of mortality and LTFU by country and type of
second-line ART from the competing risk analysis. At 3 years,
3.3% of patients (95% CI: 2.3% to 4.5%) in the TDF group in
Zambia and 4.4% (95% CI: 1.8 to 8.8) in South Africa were
FIGURE 1. Cumulative incidence of
immunological failure in Zambia (A)
and virological failure in the Republic
of South Africa (B) during the ﬁrst
three years of second-line ART. TDF,
tenofovir.
Wandeler et al J Acquir Immune Deﬁc Syndr   Volume 61, Number 1, September 1, 2012
44 | www.jaids.com  2012 Lippincott Williams & Wilkinsknown to have died. These proportions were higher in the
groups treated without TDF: 9.0% (95% CI: 6.9% to 12.7%)
in Zambia and 7.8% (95% CI: 5.8 to 10.00) in South Africa.
LTFU at 3 years was higher in Zambia than in RSA. In Zam-
bia, LTFU was somewhat higher in patients on TDF compared
with patients not on TDF, whereas the opposite was observed
in RSA: LTFU was lower in patients on TDF compared with
other patients (Figure 2). These analyses were not adjusted for
differences in patient characteristics at the start of second-line
ART and therefore have to be interpreted with caution.
Regression Analyses of Treatment Failure
and Mortality
Figure 3 presents the results from the Cox and compet-
ing risk regression analyses adjusted for age, sex, CD4 count,
time on ﬁrst-line ART, and calendar year, and meta-analyses
of these estimates. Results for immunological failure were
closely similar in Zambia and RSA (P from test of heteroge-
neity 0.99), with a combined HR comparing TDF with other
regimens of 0.60 (95% CI: 0.41 to 0.87). Similarly, the hazard
of virologic failure was reduced with TDF in RSA: HR 0.22
(95% CI: 0.07 to 0.71). Mortality was lower in patients on
a TDF-containing regimen compared with those on other reg-
imens in Zambia but not in RSA. However, CIs overlapped,
and the test of heterogeneity was not statistically signiﬁcant
(P = 0.13). The combined subdistribution HR for mortality
was 0.63 (95% CI: 0.38 to 1.05).
Results for all variables included in the models
are shown in the Supplemental Digital Content (see
Table S1, http://links.lww.com/QAI/A340, for Zambia and
see Table S2, http://links.lww.com/QAI/A340, for RSA). In
both settings, male patients and those younger than 30 years
were more likely to experience treatment failure. Time spent on
ﬁrst-line ART before switching to a second-line regimen did
not affect outcomes. Finally, in patients on TDF-containing
second-line regimens, the risk of second-line immunological
failure in the TDF-group was slightly increased if D4T was
used in the ﬁrst-line backbone, however, CIs around the
HR (adjusted for all variables listed above) were wide and
included both a decrease and increase of the risk of failure:
HR 1.30 (95% CI: 0.84 to 2.02).
FIGURE 2. Retention in care by second-line ART category and country.
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Even though several countries in southern Africa have
introduced TDF in ﬁrst-line ART, most patients who will be
failing their ﬁrst-line regimen in the coming years will not
have been exposed to TDF. As a consequence, these patients
might beneﬁt from this drug in their second-line regimen. The
comparative effectiveness of second-line regimens, including
or excluding TDF, in southern Africa is therefore of great
interest. We compared clinical outcomes between patients
receiving TDF-containing second-line ART and patients
treated with other second-line regimens in 6 ART pro-
grammes in Zambia and RSA. Overall, mortality and the rate
of treatment failure were low in this population, underlining
the beneﬁt of PI-based second-line ART in patients failing
ﬁrst-line treatment in the region.
20 In Zambia, LTFU was
similar in patients on second-line ART containing and not
containing TDF, but mortality and immunological failure
were lower in patients on TDF. In the 5 South African cohorts
with access to routine viral load monitoring the rate of viro-
logical failure was also lower in the TDF group.
In contrast to Zambia, the use of TDF was not associated
with reduced mortality in South Africa. This ﬁnding could be
the result of differences in the capacity of the health system in
South Africa compared with Zambia or reﬂect differences in
ascertainment of deaths and tracing of patients LTFU.
Confounding by indication could be another explanation: the
relatively few patients who were prescribed TDF in South
Africa before 2010 might have been a selected group of sicker
patients. Finally, the difference between the 2 countries could
reﬂect the play of chance: the CIs overlapped widely, and
a formal test of heterogeneity gave a P value of 0.13. We can
thus not exclude a similar reduction in mortality in RSA.
In both groups, mortality after 1 year of second-line
ART was somewhat lower than the 5.4% mortality observed
after a median of 15.1 months in the Médecins sans Frontières
(MSF) multicohort study of patients on second-line ART.
3
In contrast, in a study of patients virologically failing ﬁrst-
line ART in Malawi, 10% of patients on second-line ART
died during the ﬁrst 6 months.
6 The higher mortality in the
latter study might be explained by the presence of virological
failure in all patients and the very low median CD4 count at
the start of second-line ART. Furthermore, patients who are
treated in settings without access to routine viral-load moni-
toring are at risk of remaining on failing ﬁrst-line regimens
for long periods before switching to second-line ART
2,21 and
of accumulating drug resistance mutations which might limit
the efﬁcacy of some second-line regimens.
11
Studies from different regions in sub-Saharan Africa
showed a high prevalence of TDF-related resistance mutations
in patients failing ﬁrst-line ART.
10,11,22 This raised concerns on
the efﬁcacy of TDF in second-line regimens for populations
infected with subtype C HIV-1 variants. In high-income coun-
tries, the K65R mutation is present only in 2%–5% of HIV-1
subtype B infected patients failing ﬁrst-line ART.
23 In con-
trast, more than 20% of patients failing ﬁrst-line ART in an
urban public-sector ART clinic in Malawi had developed this
resistance mutation, without prior exposure to TDF.
11 Interest-
ingly, in the Malawian study, and the PharmAccess African
Studies to Evaluate Resistance (PASER), clinical outcomes
one year after initiation of second-line ART were not affected
by resistance to TDF.
6,24 Another report from PASER never-
theless argued that in light of the high prevalence of the K65R
mutation in patients failing a D4T-containing regimen, AZT
might be a better option for second-line ART than TDF.
12
Prolonged treatment with a failing D4T-containing ﬁrst-line
regimen might explain the high levels of TDF resistance
mutations in the region.
23 We found little evidence for an
association of the risk of second-line treatment failure with
the presence of D4T in the ﬁrst-line regimen, however, the
power of our study to detect smaller effects was limited.
There are several possible explanations for the superior
effect of TDF in second-line ART in Zambia and South Africa.
More than 80% of the patients not on TDF were treated with
either DDI/AZT or DDI/ABC as the NRTI backbone. Due to
its better tolerability and once-daily dosing, treatment adher-
ence might be higher in patients receiving TDF compared with
other NRTI combinations, especially those including DDI: the
higher toxicity of DDI-based regimens might have led to
poorer adherence. Wallis et al
25 and van Zyl et al
15 reported
a low prevalence of PI mutations in patients failing second-line
ART in the Republic of South Africa,
25,26 indicating that failure
was due to insufﬁcient drug levels following nonadherence,
rather than resistance. Finally, the high potency of LPV/r
monotherapy in patients without prior PI exposure could have
masked larger differences in treatment outcomes between the
2g r o u p s .
27,28 Patients on TDF-containing second-line regimens
FIGURE 3. The risk of treatment failure and death on second-
line ART containing and not containing tenofovir in Zambia
and the Republic of South Africa. The estimates shown are
hazard ratios (HR) for immunological and virological failure
and subdistribution hazard ratios (sHR) for mortality.
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mutations, including thymidine-analogue mutations and
K65R. Of note, the difference in treatment failure between
the 2 second-line regimens emerged already after 1 year in
RSA, whereas it was only apparent later during follow-up in
Zambia. This could be explained by the earlier diagnosis of
treatment failure with virological monitoring in RSA compared
with CD4 monitoring in Zambia.
To our knowledge, this is the ﬁrst study to compare
second-line regimens in southern Africa. In particular, there are
no randomized trials of second-line ART tailored to regions
where non-B HIV subtypes dominate. The main limitation of
multicohort data comparing treatments lies in the lack of
randomization and the heterogeneity between the different
treatment sites. Confounding by indication and differences
between settings in background mortality, monitoring and
treatment strategies, and health systems may have biased our
results. Of note, the proportion of patients on a TDF-containing
second-line regimen varied widely across countries and calen-
dar time, reﬂecting national treatment guidelines. However, the
association of TDF with reduced rates of treatment failure was
consistent within countries and cohorts, which adds strength to
our ﬁndings. Furthermore, more than 99% of the patients
received the same PI, thus effectively removing one potential
source of confounding. We had no data on treatment adherence,
which is known to inﬂuence ART outcomes.
29–31 Young age
and male gender were risk factors for second-line failure, prob-
ably as a consequence of the lower adherence to ART in youn-
ger patients and men.
32,33 Finally, as no genotypic resistance
data is routinely collected in southern Africa, we could not
assess the relationship between treatment failure, resistance pat-
terns, and clinical outcomes.
We did not evaluate toxicity and side effects related to
the different regimen. Most patients on non-TDF second-line
ART had DDI in their backbone. The toxicities of DDI,
including lipodystrophy, gastrointestinal intolerance, periph-
eral neuropathy, and pancreatitis, will have inﬂuenced our
results.
34,35 TDF is associated with nephrotoxicity, including
an increased risk of loss of kidney function, acute renal fail-
ure, and tubulopathy.
36,37 A recent study from South Africa
showed that preexisting renal disease was frequently exacer-
bated by the use of TDF.
38 Furthermore, patients on PI-based
regimens may be at increased risk of renal failure.
39 Screening
for renal dysfunction before the initiation of TDF-containing
regimen and close monitoring during treatment is part of
treatment guidelines and should be performed routinely.
In conclusion, we found that patients on TDF-containing
second-line ART were less likely to develop treatment failure
in all cohorts and less likely to die in Zambia than patients on
other regimens. Despite the increased prevalence of TDF-
related resistance mutations in patients failing ﬁrst-line ART in
southern Africa, TDF seems to be an effective component of
second-line ART for many patients who have not been
exposed to this drug previously. This ﬁnding is of considerable
importance, as an increasing number of TDF-unexposed
patients failing their ﬁrst-line treatment will be switched to
TDF-containing second-line regimen in the coming years.
Second-line ART is becoming more available in sub-Saharan
Africa, but most ART programmes in the region do not have
access to individual genotypic resistance data. Thus, random-
ized trials comparing the efﬁcacy and toxicities of different
second-line regimens are urgently needed to inform clinical
practice and guidelines.
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